References
- Melton LJ, Atkinson EJ, O'Fallon WM, et al. Long-term fracture prediction by bone mineral density assessed at different skeletal sites. J Bone Miner Res 1993;8:1227–33
- Manologas SC, Jilka RL. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995;332:305–11
- Eastell R, Delmas RD, Hodgson SF, et al. Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, kinetics, and biochemical markers. J Clin Endocrinol Metab 1988;67:741–8
- Podenphant J, Engel U. Regional variations in histomorphometric bone dynamics from the skele-ton of an osteoporotic woman. Calqf Tissue Int 1987;40:184–8
- Delmas PD. Biochemical markersofbone turnover in osteoporosis. In Riggs BL, Metton U, eds. Osteoporosis: Etiology, Diagnosis and Management. New York: Raven Press, 1988;297
- Stepan JJ, Vokrouhlicka J. Comparison of bio-chemical markers ofbone remo delling in the assess-ment of the effects of alendronate on bone in postmenopausal osteoporosis. Clin Chim Acta 1999;288:121–35
- Kivirikko KI. Excretion of urinary hydroxy-proline peptide in the assessment of bone collagen deposition and resorption. In Frame B, Potts JT, eds. Clinical Disorders of Bone and Mineral Metabolism. Amsterdam: Excerpta Medica, 1983;105
- Seibel MJ. Molecular markers of bone turnover: biochemical, technical and analytical aspects. Osteoporos Int 2000;11:518–29
- Eyre DR. Cross-link maturation in bone collagen. In Veis A, eds. The Chemistry and Biology of Mineral-ized Connective Tissues. Amsterdam: Elsevier, 1981;51
- Muller A, HeM G, Franke S, et al. Quantitative analysis of pyridinium cross-links of collagen in the synovial fluid of patients with rheumatoid arthritis using high-performance liquid chromatography. Rheumatol Int 1996;16:23–8
- Uelbelhart D, Gineyts E, Chapuy MC, et al. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 1990;8:87–96
- Seyedin SM, Kung VT, Daniloff YN. Immuno-assay for urinary pyridinoline. The new marker of bone resorption. J Bone Miner Res 1993;8:635–41
- Eastell R, Robins SP, Colwell T, et al. Evaluation of bone turnover in type 1 osteoporosis using biochemical markers specific for both bone forma-tion and bone resorption. Osteoporosis Int 1993;3: 255–60
- Hansen MA, Overgaard K, Riis BJ, Christiansen C. Role of peak bone mass and loss in postmeno-pausal osteoporosis. Br Med J1991;303:961–4
- Al-Dehaimi AW, Blumsohn A, Eastell R. Serum galactosyl hydroxylysine as a biochemical marker of bone resorption. Clin Chem 1999;45:676–81
- Garnero P, Grimaux M, Demiaux B, et al. Measurement of serum osteocalcin with a human-specific two-site radioimmunoassay. J Bone Miner Res 1992;7:1389–97
- Hassager C, Colwell A, Assiri AMA, et al. Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross-links: a longitudinal and cross-sectional study. Clin Endo-crinol 1992;37:45–50
- Garnero P, Shih WJ, Gineyts E, et al. Comparision of new biochemical markers of bone turn-over in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693–700
- Delmas PD, Wahner HW, Mann KG. Assessment of bone turnover in postmenopausal osteoporosis by measurement o f serum bone GLA-protein. JLab Clin Med 1983;102:470–6
- Rogers A, Hannon RA, Eastell R. Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res 2000;15:1398–404
- Nilas L, Christiansen C. The pathophysiology of peri- and post-menopausal bone loss. Br J Obstet Gynaecol 1989;96:580–7
- Poullies JM, Tremollieres E, Ribot C. The effects of menopause on longitudinal bone loss from the spine. Calqf Tissue Int 1993;52:340–3
- The Writing Group for the PEPI. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin inter-ventions (PEPI) trial. JAMA 1996;276:1389–96
- Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 1998;338:485–92
- Bush TL, Wells HB, James MK. Effects of hormone replacement therapy on bone mineral density. JAMA 1996;276:1389–96
- Johnston CC, Melton U, Lindsay R, Eddy DM. Clinical indications for bone mass measurement. J Bone Miner Res 1989;4:1–28